Skip to main content

Table 2 Univariate Cox proportional hazard model of bone marrow suppression induced by S-1

From: Impact of relative dose intensity on bone marrow suppression induced by S-1: retrospective observational study

Variables HR 95% CI p value
Male gender 1.11 0.77–1.64 0.58
Age (years) 0.99 0.97–1.01 0.27
Height (cm) 1.01 0.99–1.03 0.57
Body weight (kg) 1.01 0.99–1.02 0.41
BMI (kg/m2) 1.02 0.97–1.07 0.50
BSA (m2) 1.50 0.53–4.19 0.44
Grade ≥ 2 leukopeniaa 0.78 0.24–1.86 0.61
Grade ≥ 2 neutropeniaa 0.66 0.20–1.61 0.39
Grade ≥ 2 lymphocytopeniaa 3.79 1.31–8.78 < 0.05
Grade ≥ 2 anemiaa 0.71 0.30–1.41 0.35
AST (IU/L) 1.00 0.99–1.01 0.91
ALT (IU/L) 1.00 0.99–1.01 0.76
Total bilirubin (mg/dL) 0.65 0.40–0.99 < 0.05
Serum albumin (g/dL) 0.78 0.50–1.24 0.29
eGFRb (mL/min/1.73 m2) 1.00 0.99–1.01 0.98
Gastrointestinal cancer 1.09 0.71–1.64 0.68
Clinical cancer stage ≥III 0.99 0.64–1.60 0.97
RDIc > 70% 1.54 0.99–2.48 < 0.05
RDIc > 75% 1.52 1.05–2.21 < 0.05
RDIc > 80% 1.39 0.97–1.99 0.07
Presence of combination chemotherapy 1.46 0.99–2.13 0.06
Prior history of cytotoxic chemotherapy 1.21 0.82–1.74 0.34
  1. HR hazard ratio, 95% CI 95% confidence interval, BMI body mass index, BSA body surface area, AST aspartate transaminase, ALT alanine aminotransferase, eGFR estimated glomerular filtration rate, RDI relative dose intensity
  2. aGrade ≥ 2 leukopenia, neutropenia, lymphocytopenia, anemia, and thrombocytopenia at the initiation of S-1 treatment were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. No patient had Grade ≥ 3 thrombocytopenia.
  3. beGFR was calculated using a prediction equation.
  4. cRDI is the ratio of the actual dose intensity administered and the planned dose intensity.